NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, highlighted the potential of its broad-spectrum antiviral candidate NV-387 in response to the ongoing Bundibugyo Ebola outbreak in the Democratic Republic of Congo and Uganda. The company stated that the oral drug candidate could offer a differentiated approach if proven effective against the virus strain, emphasizing NV-387's proposed mechanism targeting viral cell attachment pathways common across filoviruses.
This positions the candidate as a potential pandemic preparedness tool for Ebola and related viral threats, as detailed in the full press release at https://ibn.fm/mm3Z5.
NV-387 is NanoViricides' lead drug candidate, a broad-spectrum antiviral drug planned for development against RSV, COVID-19, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox and Measles. The company's advanced drug candidate NV-HHV-1 targets Shingles. NanoViricides is currently focused on advancing NV-387 into Phase II human clinical trials.
The company's platform technology is based on the TheraCour® nanomedicine technology, licensed from TheraCour Pharma, Inc. NanoViricides holds a worldwide exclusive perpetual license for several drugs with specific targeting mechanisms for treating human viral diseases including HIV/AIDS, Hepatitis B and C, Rabies, Herpes Simplex and Varicella-Zoster viruses, Influenza, Asian Bird Flu, Dengue, Japanese Encephalitis, West Nile, Ebola/Marburg, and certain Coronaviruses. The company intends to obtain licenses for RSV, Poxviruses, and Enteroviruses if initial research is successful.
The recent Ebola outbreak underscores the urgent need for effective antiviral treatments. NV-387's oral formulation and proposed broad-spectrum activity may provide a significant advantage over existing injectable therapies, particularly in resource-limited settings. However, the company cautions that the path to drug development is lengthy and requires substantial capital, with no assurance of success in clinical trials.
Investors can find the latest news and updates regarding NNVC at https://ibn.fm/NNVC. This announcement highlights NanoViricides' strategic focus on pandemic preparedness, leveraging its nanoviricide technology to address emerging viral threats.
